FDA Accelerated Approval of Pembrolizumab for Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma

On December 19, 2018, the Food and Drug Administration granted accelerated approval to pembrolizumab (KEYTRUDA, Merck & Co. Inc., Whitehouse Station, NJ) for adult and pediatric patients with recurrent locally advanced or metastatic Merkel cell carcinoma (MCC). Approval was based on Cancer Immun...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Oncologist
Main Authors: Bradford, Diana, Demko, Suzanne, Jin, Susan, Mishra‐Kalyani, Pallavi, Beckles, Aaliyah R., Goldberg, Kirsten B., Lemery, Steven, Ward, Ashley, Keegan, Patricia, Pazdur, Richard
Formato: Artigo
Idioma:Inglês
Publicado em: John Wiley & Sons, Inc. 2020
Assuntos:
Regulatory Issues: FDA
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7356706/
https://ncbi.nlm.nih.gov/pubmed/32272501
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0184
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados